Press Releases April 8, 2026 08:00 PM

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

Fate Therapeutics Announces Participation in Multiple Q2 2026 Investor Conferences

By Leila Farooq FATE
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
FATE

Fate Therapeutics, a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies, will participate in five major healthcare investor conferences in Q2 2026. These events will provide updates and engagement opportunities with investors through presentations and webcast sessions.

Key Points

  • Fate Therapeutics will engage investors at five leading healthcare conferences in Q2 2026, including virtual and in-person events across major US cities.
  • The company focuses on developing first-in-class iPSC-derived cellular immunotherapies targeting cancer and autoimmune diseases.
  • Using proprietary iPSC product platform, Fate has a leading position in multiplexed-engineered iPSC lines and off-the-shelf cell product manufacturing, indicative of advancing clinical pipeline.

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026.

25th Annual Needham Virtual Healthcare Conference

Location: Virtual

Date: April 14th  

Bank of America Healthcare Conference 2026

Location: Encore at the Wynn - Las Vegas, NV        

Date: May 13th

H.C. Wainwright 4th Annual BioConnect Investor Conference 

Location: Nasdaq - New York, NY        

Date: May 19th

2026 Jeffries Global Healthcare Conference

Location: Marriott Marquis - New York, NY

Date: June 4th

Goldman Sachs 47th Annual Global Healthcare Conference

Location: Loews Miami Beach Hotel - Miami Beach, FL

Date: June10th

The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days on the Company’s website following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
[email protected]


Risks

  • Clinical-stage biopharmaceutical nature entails inherent development and regulatory approval risks, which may impact project timelines and commercial viability.
  • Market reception and investor interest depend on the data and progress shared during upcoming conferences; insufficient positive data may temper enthusiasm.
  • Competitive and rapidly evolving immunotherapy sector faces technological and commercial challenges, impacting Fate’s ability to maintain leadership and capture market share.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026